ContraFect Corporation (CFRXQ)

-99.55% (1Y)

Market Cap	1.07K
Revenue (ttm)	n/a
Net Income (ttm)	-24.14M
Shares Out	10.70M
EPS (ttm)	-5.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,863
Average Volume	2,506
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 1.0400
Beta	-11.30
RSI	35.70
Earnings Date	n/a

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 23
• Stock Exchange: OTCMKTS
• Ticker Symbol: CFRXQ